Tevogen Inc.

Tevogen Inc. (Nasdaq: TVGN) is a clinical-stage biopharmaceutical company focused on developing off-the-shelf, allogeneic T-cell receptor-based immunotherapies targeting infectious disease and oncology indications. The company entered the public markets through a SPAC business combination and operates in the biotechnology and life sciences sector. On August 3, 2026, Tevogen filed a DEF 14A definitive proxy statement with the SEC, accession number 0001493152-26-035757, outlining matters subject to an upcoming shareholder vote. The company is currently in its post-combination phase, advancing its clinical pipeline as a publicly traded entity. Sign up for full data, filing history, and deal analytics on TVGN at SpacDesk.